Product Images Desvenlafaxine
View Photos of Packaging, Labels & Appearance
- AHP60721
- 50 mg Desvenlafaxine Extended-Release Tablet Blister - Blister
- 50 mg Desvenlafaxine Extended-Release Tablets Carton - Carton
- Figure 1: Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics - Figure 1
- Figure 2: Effect of Other Drugs on Desvenlafaxine Pharmacokinetics - Figure 2
- Figure 3: Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs - Figure 3
- Figure 4: Estimated Proportion of Relapses vs. Number of Days Since Randomization (Study 5) - Figure 4
- Figure 5: Estimated Proportion of Relapses vs. Number of Days Since Randomization (Study 6) - Figure 5
- Structural Formula - Structure
Product Label Images
The following 9 images provide visual information about the product associated with Desvenlafaxine NDC 60687-607 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
AHP60721
50 mg Desvenlafaxine Extended-Release Tablet Blister - Blister
50 mg Desvenlafaxine Extended-Release Tablets Carton - Carton
Desvenlafaxine Extended-Release Tablets, NDC 60687-607-21, come in a package of 30 tablets (3 x 10) for Rx use. Each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg sty. It is recommended to swallow tablets whole and to dispense with the accompanying Medication Guide to each patient. The usual dosage information can be found in the packaging. Store at 20°C - 25°C (68°F -77°F) and keep out of reach of children. The drug product contained in this package is from NDC # 50540400, West Ward Pharmaceuticals Core, and it is distributed by American Health Packaging 760721 in Columbus, Ohio.*
Figure 1: Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics - Figure 1
Figure 2: Effect of Other Drugs on Desvenlafaxine Pharmacokinetics - Figure 2
This appears to be a statistical analysis output related to the effect of Ketoconazole on the pharmacokinetics of a drug via CYP3A4 inhibition. It includes information on the geometric mean ratio and confidence intervals for changes observed in Cmax, AUC, and T. However, without further context or information it is difficult to provide a specific description or interpretation.*
Figure 3: Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs - Figure 3
Figure 4: Estimated Proportion of Relapses vs. Number of Days Since Randomization (Study 5) - Figure 4
The text seems to be a chart displaying estimates of the proportion of patients experiencing relapse. There are four values presented, 50%, 4%, 30%, and 20%. The rest of the text appears to be axis labels and is not applicable to the description.*
Figure 5: Estimated Proportion of Relapses vs. Number of Days Since Randomization (Study 6) - Figure 5
The text describes a graph showing the estimated proportion of patients experiencing relapse over time (in days) following randomization. It compares two treatments, Desvenlafaxine and Placebo. The y-axis is not labeled with specific values but appears to show a range from 0% to 200%.*
Structural Formula - Structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
